Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.77 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.77 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20876569 | 1.00 | CYP2B6 (0.77) | CYP2B6TENT4ATENT4B | |
| SCHEMBL19966858 | 0.91 | CYP2B6 (0.64) | CYP2B6TENT4ATENT4B | |
| SCHEMBL29579831 | 0.91 | CYP2B6 (0.64) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20876573 | 0.90 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20876562 | 0.90 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20876563 | 0.90 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20876593 | 0.90 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20876574 | 0.90 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20876594 | 0.90 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B | |
| SCHEMBL30137678 | 0.90 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255428-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-13 | — | — | US | claimed |
| EP-3692040-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-08-12 | — | — | EP | claimed |
| WO-2019069293-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | claimed |
| US-20250066361-A1 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-27 | — | — | US | disclosed |
| US-12221444-B2 | 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-11 | — | — | US | disclosed |
| EP-4180431-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-05-17 | — | — | EP | disclosed |
| EP-3692040-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-20220144834-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-05-12 | — | — | US | disclosed |
| US-20210330678-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | disclosed |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| EP-3692040-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019069293-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
| WO-2018047109-A1 | POLYCYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018047109-A1 | POLYCYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221444-B2 | 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use | HAVCR2, HBS1L, HBG1 | CYP2B6 65/4885TENT4A 936/4885TENT4B 558/4885 |
| US-20210330678-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | PARP15, PAPSS1, PGA5 | CYP2B6 3451/4885TENT4A 154/4885TENT4B 109/4885 |
| US-20250066361-A1 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | HAVCR2, HMBS, HBS1L | CYP2B6 19/4885TENT4A 1040/4885TENT4B 746/4885 |
| US-20220144834-A1 | Chemical Compounds | HAVCR2, HBS1L, HLA-B | CYP2B6 254/4885TENT4A 2212/4885TENT4B 1797/4885 |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | HAVCR2, HBS1L, HLA-B | CYP2B6 254/4885TENT4A 2212/4885TENT4B 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.